A New HPLC Method for Analysis of Natural Monacolin K in Red Yeast Rice Pharmaceutical Preparations

Sabry OMM*
Pharmacognosy Department-Faculty of Pharmacy, Cairo University, Cairo-11562, Egypt

Abstract

Monacolin K (lovastatin or mevinolin) is a naturally occurring hypocholesterolemic statin used to prevent cardiovascular diseases for those persons suffering from hypercholesterolemia, a condition characterized by very high levels of cholesterol in the blood. It is originally derived from the fungus Monascus ruber and Monascus purpureus family Monascaceae. Monacolin K is a lactone polyketide derived compound converted in the body to the active form, B-hydroxy acid of monacolin K. It acts by inhibiting the hepatic HMG-CoA Reductase enzyme. In this paper, we report a selective precise and accurate new HPLC method for analysis of both lactone form and acid form of monacolin k in red rice pharmaceutical preparations.

Keywords: Red yeast rice; Monascus purpureus; Monacolin K; Lovastatin; HPLC; Diode array detector (DAD)

Introduction

Red yeast rice is a fermented food product produced by inoculating Monascus purpureus into steamed rice [1]. Extracts from red yeast rice are well known for their content of starch, sterols, isoflavones, mono-unsaturated fatty acids and monacolins. The functions of red yeast rice products include reducing blood serum cholesterol [2], anti-fatigue [3], fighting Alzehimer [4], preventing obesity development [5], and prevention of diabetes development [6]. Monacolins are polyketide derived compounds that has the ability of lowering the blood lipid levels. Increased levels of cholesterol and triglycerides are known to be risk factors for developing coronary artery diseases. Lipid-lowering agents that inhibit HMG coenzyme-A reductase are now prominent among the drugs of choice for treating hypercholesterolemia. Monacolin k (Figure 1) is a potent inhibitor of HMG-CoA reductase, the rate limiting enzyme in cholesterol biosynthesis and has been demonstrated to be effective in reducing both cholesterol and triglyceride. Fourteen naturally occurring monacolin products were identified in red yeast rice (Figure 2), those are monacolin K, monacolin J, monacolin L, monacolin M, monacolin X, and their hydroxy acid form, as well as dehydromonacolin K, dihydromonacolin L, compactin, 3α hydroxy-3,5-dihydromonacolin L [7]. Monacolins are a group of statins existing in both lactone forms and hydroxyl acid forms [8]. Monacolin K is an active pharmaceutical ingredient in the Monascus capsule. Its role is to reduce serum total cholesterol, triglyceride, and LDL cholesterol, increase HDL cholesterol, treat for hyperlipidemia and cardio-cerebrovascular, diseases caused by hyperlipidemia and atherosclerosis. Statins are a novel class of drugs widely used for the treatment of hypercholesterolemia and atherosclerosis commonly known to act as 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors (Figure 3) [9,10]. High-performance liquid chromatography (HPLC) shows many advantages in the chemical analysis of herbal medicines and their preparations, such as high sensitivity, reproducibility, good resolution, linearity, the ability to analyze multiple constituents and the ease of automation. Because of the acidity of statin compounds, acidic modifiers are usually used to suppress their ionization and to achieve optimal separation. The modifier used here is di-hydrogen phosphate potassium salt [11]. In this research paper we are using the usefulness of instability of the Monacolin K lactone compound [8-[2-(4-hydroxy-6-oxo-oxan-2-yl) ethyl] -3,7-dimethyl-1,2,3,7,8,8a-3,7-dimethyl-1,2,3,7,8,8a-hexahydonaphthalen-1-yl] 2-methylbutanoate which can be caused by hydrolysis in aqueous media to determine both the lactone and acid form (Figure 4) [12].

The determination of Monacolin K in the capsule of Monascus has great significance for the control of clinical therapy. So, a simple, rapid, and sensitive analytical method for separation and determination of Monacolin K in the capsule of Monascus is of great interest. HPLC has been applied for the qualitative and quantitative analysis of Monacolin K in the capsule [11,13]. The objective of this paper was to quantify the amount of monacolin k in commercial pharmaceutical preparations containing M. purpureus existing in both lactone form and hydroxy acid form using technology of hyphenated HPLC/DAD. The content of monacolin K in red yeast rice commercial preparation was estimated referenced to standard commercially available monacolin K lactone form (MKL).

Experimental

Materials and chemicals

Capsules of red yeast (Biochol BIO PHARMA EGYPT S.A.E.) were purchased from the Egyptian Drugstores. Reference standard Monacolin K and KH2PO4, analysis reagent grade were purchased from sigma. Acetonitrile HPLC grade and Methanol HPLC grade were purchased from Merck.

Equipment (Apparatus and chromatographic conditions)

HPLC was performed with a Dionex ultimate 3000 isocratic chromatograph equipped with Ultimate 3000 pump, Ultimate 3000
column compartment, controlled by Ultimate 3000 autosampler and Ultimate 3000 photodiode array detector (PAD) was used for peak purity test and analysis of compounds. Analysis was performed on a Dionex octadecyl silyl silica gel column (250 mm x 4.6 mm I.D., 5 μm particle size). The mobile phase was Isocratic acetonitrile (A) and 50mM KH2PO4 pH 3.5 (B) 60:35. The injection volume was 20 μl and the samples were monitored at 237 nm. A constant flow-rate of 1.5 ml/min was used during analysis. HPLC grade solvents and bi-distilled...
water were used in the chromatographic studies. All chromatographic experiments were performed at constant column temperature 40°C.

**Procedure**

**Sample preparation**

150 mg of the red yeast capsule (Biochol Capsule) content were accurately weighed and transferred to 100 ml volumetric flask. 80 ml of mobile phase (acetonitrile-50M KH₂PO₄ pH 3.5 (60:35)) were added. Mixture was sonicated for 10 minutes to be dissolved. Volume was completed to 100 ml with the mobile phase. Sample was filtered through a 0.45 μm syringe membrane filter prior to injection (20 μL) into HPLC.

**Preparation of standard solutions**

**Preparation of standard Monacolin K lactone form (MKL):** An accurately weighed amount of lovastatin (Monocolin K) 25 mg (99.5% purity) was transferred to 100 ml volumetric flask. 70 ml of mobile phase (acetonitrile - 50mM KH₂PO₄ pH 3.5 (60:35)) was added. Mixtures were sonicated for 10 minutes to be dissolved. Dilution with mobile phase to 100 ml was carried out to form the parent standard solution.

**Standard Solution 5 (0.0398 mg/ml):** 4 ml of the parent standard solution was transferred to a 25 ml volumetric flask; volume was completed and adjusted to 25 ml with the mobile phase acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35).

**Standard Solution 4 (0.0199 mg/ml):** 2 ml of the parent standard solution was transferred to a 25 ml volumetric flask; volume was completed and adjusted to 25 ml with the mobile phase acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35).

**Standard Solution 3 (0.00995 mg/ml):** 1 ml of the parent standard solution was transferred to a 25 ml volumetric flask; volume was completed and adjusted to 25 ml with the mobile phase acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35).

**Standard Solution 2 (0.00497 mg/ml):** 5 ml of the Standard Solution 3 was transferred to a 10ml volumetric flask; volume was completed and adjusted to 10 ml with the mobile phase acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35).

**Standard Solution 1 (0.00298 mg/ml):** 3 ml of the Standard Solution 2 was transferred to a 5 ml volumetric flask; volume was completed and adjusted to 5 ml with the mobile phase acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35).

**Preparation of standard Monacolin K acid form (MKA):** Standard Solution 5b (0.0398 mg/ml): 2 ml of the Standard Solution 5 were mixed with 2 ml 0.1 N NaOH and kept for 2 h at 30°C. The mixture was dried under vacuum, and then dissolved in 2 ml acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35). The solution was filtered through a 0.45 μm membrane syringe filter prior to analysis using HPLC.

**Standard Solution 4b (0.0199 mg/ml):** 2 mls of the Standard Solution 4 were mixed with 2 ml 0.1 N NaOH and kept for 2 h at 30°C. The mixture was dried under vacuum, and then dissolved in 2 ml acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35). The solution was filtered through a 0.45 μm membrane syringe filter prior to analysis using HPLC.

**Standard Solution 3b (0.00995 mg/ml):** 2 mls of the Standard Solution 3 were mixed with 2 ml 0.1 N NaOH and kept for 2 h at 30°C. The mixture was dried under vacuum, and then dissolved in 2 ml acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35). The mixture was filtered through a 0.45 μm membrane syringe filter prior to analysis using HPLC.

**Standard Solution 2b (0.00497 mg/ml):** 2 mls of the Standard Solution 2 were mixed with 2 ml 0.1 N NaOH and kept for 2 h at 30°C. The mixture was dried under vacuum, and then dissolved in 2 ml acetonitrile-50 mM KH₂PO₄ pH 3.5 (60:35). The solution was filtered through a 0.45 μm membrane syringe filter prior to analysis using HPLC.

**Calibration curves**

The calibration curve for Monacolin K lactone form (Figure 5) was obtained by plotting the peak areas of Monacolin K lactone form and Monacolin K acid form versus concentration of Monacolin K lactone form over the range of 0.002985-0.039800 mg/ml. The calibration curve for Monacolin K acid form (Figure 6) was obtained by plotting the peak areas of Monacolin K acid form versus concentration of Monacolin K lactone form (MKL) over the range of 0.002985-0.039800 mg/ml. The data of analysis of the calibration curve are shown in (Table 1 and 2). The recoveries of Monacolin K lactone form (MKL) and Monacolin K acid form (MKA) were found to be in the range of 99-101%. The proposed HPLC method was applied to the determination of equivalent amount of Monacolin K lactone form (MKL) in the Biochol capsule dosage form.

**Method development**

The procedure was conducted on the liquid chromatography with photodiode array detector was optimized by testing various system conditions. General reverse-phase C18 and ODS columns were used, and several different elution systems were trialed. The resolution and symmetry factors of peaks as monacolin K with its neighboring peaks were satisfied by using acetonitrile-water system. The symmetry and resolution was increased by lowering the pH value of elution (pH 3.5). Several aqueous solutions such as the phosphoric buffer, acetic acid as well as dilute phosphoric acid and dilute trifluoroacetic acid (TFA) together with an organic phase of methanol or acetonitrile etc. were used for the condition optimization. The results suggested a system composed of acetonitrile – 50 mM KH₂PO₄ pH 3.5 (60:35) as an ideal system for the separation of the monacolin compounds. The photodiode array detector was set at 210-350 nm and the chromatogram detected at 237 nm. The column temperature was set at 40°C, and the injection volume was 20 μL. The accuracy of the method was determined by calculating recoveries of Monacolin K by method of standard additions. Selection of mobile phase was performed based on resolution and theoretical plates obtained for both monacolin K lactone form and acid form. The mobile phase acetonitrile and 50 mM KH₂PO₄ (60:35) was found to be satisfactory and gave two well-resolved peaks for Monacolin K lactone form and Monacolin K acid form. The retention time for Monacolin K acid form and Monacolin K lactone form were 5.621 min and 9.07 min, respectively (Figure 7) UV spectra of both the monacolin K lactone form and monacolin K acid form showed that both the drugs absorbs appreciably at 237 nm so, 237 nm was selected as the detection wavelength in HPLC.
Results

From the constructed standard calibration curve, Concentrations of Monacolin K lactone form and Monacolin K acid form were found to be 0.0035 mg/ml and 0.0027 mg/ml. The total concentration of Monacolin K was found to be 0.0062 mg/ml. Monacolin K in 100 ml sample solution (150 mg powdered red yeast) is 0.62 mg. Concentration of monacolin K in 600 mg red yeast capsule (Biochol) is 2.48 mg/capsule (103.3% of the corresponding labeled amount) (Table 3).

Discussion

The results of the experiment demonstrate that the proposed HPLC method is suitable for the determination of Monacolin K content in the commercial Red yeast rice capsule. In addition, the method is reliable, simple and sensitive.

Conclusion

This work is the first work that can show how to determine both Monacolin K lactone form (MKL) and monacolin k acid form (MKA) in the complex extract of the Red Yeast Rice Pharmaceutical Preparations by the powerful HPLC technique.

References

1. Shi YC, Pan TM (2011) Beneficial effects of Monascus purpureus NTU 568-fermented products: a review. Appl Microbiol Biotechnol 90: 1207-1217.
2. Lee CL, Tsai TY, Wang JJ, Pan TM (2006) In vivo hypolipidemic effects and safety of low dosage Monascus powder in a hamster model of hyperlipidemia. Appl Microbiol Biotechnol 70: 533-540.
3. Wang JJ, Shieh MJ, Kuo SL, Lee CL, Pan TM (2006) Effect of red mold rice on antifatigue and exercise-related changes in lipid peroxidation in endurance exercise. Appl Microbiol Biotechnol 70: 247-253.
4. Lee CL, Kuo TF, Wu CL, Wang JJ, Pan TM (2010) Red mold rice promotes neuroprotective SAPPalpha secretion instead of Alzheimer’s risk factors and amyloid beta expression in hyperlipidemic Abeta40-infused rats. J Agric Food Chem 58: 2230-2238.
5. Jou PC, Ho BY, Hsu YW, Pan TM (2010) The effect of Monascus secondary polyketide metabolites, monascin and ankaflavin, on adiogenes and lipolysis activity in 3T3-L1. J Agric Food Chem 58: 12703-12709.
6. Shi YC, Pan TM (2010) Characterization of a Multifunctional Monascus Isolate NTU 568 with High Azaphilone Pigments Production. Food Biotechnol 24: 349-363.
7. Li YG, Zhang F, Wang ZT, Hu ZB (2004) Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 35: 1101-1112.
8. Juzlova P, Martinkova L, Kren V (1996) Secondary metabolites of the fungus Monascus: a review. J Ind Microbiol 16: 163-170.
9. Budavari S, O’neil M, Smith A, Heckelman P, Obenchain J (1996) The Merck Index: Encyclopedia of Chemicals, Drugs and Biologicals (Merck Index). (12th edn) Merck & Co Inc, USA Pp: 1741.
10. Gennaro AR (2000) Remington: The Science and Practice of Pharmacy. (20th edn) Lippincott Williams & Wilkins, USA.
11. Huang HN, Hua YY, Bao GR, Xie LH (2006) The quantification of monacolin k in some red yeast rice from fujian province and the comparison of the other products. Chem Pharm Bull 54: 687-689.
12. Miao XS, Metcalf CD (2003) Determination of cholesterol-lowering statin drugs in aqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr A 135:131-141.
13. Zhang XQ, Chou FR (1997) J Chin Med 22: 222-224.

| Sample Name | Conc. (mg/ml) | Ret. Time | Area (mAU*min) | Height (mAU) |
|-------------|--------------|-----------|----------------|--------------|
| Std 1       | 0.00299      | 9.05      | 2.0008         | 8.25         |
| Std 2       | 0.00498      | 9.04      | 3.2806         | 13.33        |
| Std 3       | 0.00995      | 9.06      | 6.4449         | 26.47        |
| Std 4       | 0.0199       | 9.05      | 13.1608        | 54.56        |
| Std 5       | 0.0398       | 9.06      | 25.8249        | 107.81       |

Table 2: Concentrations (mg/ml) and peak areas of standard Monacolin K lactone form.

| Sample Name | Conc. (mg/ml) | Ret. Time | Area (mAU*min) | Height (mAU) |
|-------------|--------------|-----------|----------------|--------------|
| Std 1a      | 0.00299      | 5.621     | 2.6677         | 11           |
| Std 2a      | 0.00498      | 5.62      | 4.3741         | 17.77        |
| Std 3a      | 0.00995      | 5.62      | 6.5933         | 35.29        |
| Std 4a      | 0.0199       | 5.62      | 17.5477        | 72.75        |
| Std 5a      | 0.0398       | 5.62      | 34.4332        | 142.76       |

Table 3: Concentration of monacolin K in the sample prepared.

![Calibration Curve 2](image1)

Figure 6: Calibration curve of Monacolin K acid form.

![HPLC chart of red yeast rice capsule](image2)

Figure 7: HPLC chart of red yeast rice capsule.